The research team of Prof. Dr. Didier Y.R. Stainier has been honored with the prestigious Proof of Concept (PoC) grant by the European Research Council (ERC).
With a new therapeutic approach Stainier and colleagues aim to treat Duchenne Muscular Dystrophy, a severe neuromuscular disease caused by mutations in the dystrophin gene.
The use of antisense oligonucleotides (ASOs) to upregulate utrophin, a functional analog of dystrophin, offers a mutation-independent therapy for all DMD patients.
Read more: https://www.mpi-hlr.de/394092/news_publication_25060260_transferred
You need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from Turnstile to submit the form. Please note that doing so will share data with third-party providers.
More Information
